Avita (4735) reported revenue of NT$105.1 million for Oct 2026, +61.5% year on year and +4.3% from the previous month. Revenue for Jan–Oct 2026 was NT$910.7 million (+20.9% year on year).
Year-on-year revenue growth: 4 months in a row. →
In Oct 2026, it ranked No. 71 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$105.1 million | +61.5% | +4.3% |
| Sep 2026 | NT$100.8 million | +37.0% | -1.1% |
| Aug 2026 | NT$102 million | +23.6% | -11.2% |
| Jul 2026 | NT$114.8 million | +43.1% | +39.7% |
| Jun 2026 | NT$82.1 million | -14.9% | -2.4% |
| May 2026 | NT$84.1 million | +3.0% | -21.9% |
| Apr 2026 | NT$107.7 million | +43.7% | +5.3% |
| Mar 2026 | NT$102.3 million | +17.4% | +99.9% |
| Feb 2026 | NT$51.2 million | +22.7% | -15.6% |
| Jan 2026 | NT$60.6 million | -13.1% | -42.1% |
| Dec 2025 | NT$104.7 million | +55.3% | +32.7% |
| Nov 2025 | NT$78.8 million | -2.8% | +21.1% |
| Oct 2025 | NT$65.1 million | +8.5% | -11.5% |
| Sep 2025 | NT$73.6 million | -32.7% | -10.9% |
| Aug 2025 | NT$82.5 million | +4.2% | +2.9% |
| Jul 2025 | NT$80.2 million | -0.7% | -16.9% |
| Jun 2025 | NT$96.5 million | +1.8% | +18.1% |
| May 2025 | NT$81.7 million | +23.1% | +9.0% |
| Apr 2025 | NT$75 million | -19.6% | -13.9% |
| Mar 2025 | NT$87.1 million | -8.7% | +109.0% |
| Feb 2025 | NT$41.7 million | +22.9% | -40.3% |
| Jan 2025 | NT$69.8 million | +6.0% | +3.5% |
| Dec 2024 | NT$67.4 million | +46.8% | -16.9% |
| Nov 2024 | NT$81.1 million | +58.5% | +35.1% |
| Oct 2024 | NT$60 million | +4.3% | -45.1% |
Jan–Oct 2026 cumulative: NT$910.7 million (+20.9% YoY)
Other Biotech & Medical companies
Compare with peers: Avita vs PEC / Avita vs Lotus Pharm / Avita vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
舊客戶新產品出貨增加。
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16